Begin main content

Pomalyst in combo with dexamethasone and bortezomib for Multiple Myeloma (second-line or beyond) – Details

Project Number pCODR 10165
Brand Name Pomalyst
Generic Name Pomalidomide
Tumour Type Myeloma
Indication Multiple Myeloma (second-line or beyond)
Funding Request Pomalidomide in combination with dexamethasone and bortezomib for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Review Status Pending
Pre Noc Submission Yes
NOC Date
Manufacturer Celgene Inc.
Submitter Celgene Inc.
Submission Date (Target Date) March 7, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ March 21, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.